Regulatory Agios mulls early FDA filing for sickle cell therapy PharmaphorumAgios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.RegulatoryHematologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months. RegulatoryHematologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyoutNext: A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
